加载中...

MedXY AI/MedXY News/Tag: heart failure

MedXY News

EnglishTag

heart failure

129 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms: A Multinational Cohort Review

Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms: A Multinational Cohort Review

This review evaluates AI algorithms predicting heart failure risk from noisy single-lead ECGs, synthesizing evidence from large multinational cohorts, highlighting improved risk stratification with AI-ECG models beyond traditional clinical

Section: AIDec 5, 2025

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was

Section: Cardiology

Dec 5, 2025

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a

Section: CardiologyDec 4, 2025

Prioritizing SGLT2 Inhibitors Over MRAs as Third-Line Therapy in HFrEF? Nationwide Cohort Shows Lower Mortality with SGLT2 Initiation

Prioritizing SGLT2 Inhibitors Over MRAs as Third-Line Therapy in HFrEF? Nationwide Cohort Shows Lower Mortality with SGLT2 Initiation

A Danish nationwide cohort study found that initiating SGLT2 inhibitors rather than mineralocorticoid receptor antagonists (MRAs) as the third foundational therapy after RASI and beta‑blocker in HFrEF was associated with lower all‑cause and

Section: CardiologyDec 2, 2025

Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds

Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds

In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or th

Section: CardiologyNov 29, 2025

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.

Section: CardiologyNov 29, 2025

Intracoronary Wharton’s Jelly Mesenchymal Stem Cells After STEMI Reduce Incident Heart Failure: Phase 3 PREVENT-TAHA8 Results

Intracoronary Wharton’s Jelly Mesenchymal Stem Cells After STEMI Reduce Incident Heart Failure: Phase 3 PREVENT-TAHA8 Results

A phase 3 randomized trial found intracoronary infusion of allogeneic Wharton’s jelly mesenchymal stem cells (WJ-MSCs) after STEMI reduced new-onset heart failure and HF readmissions and improved LVEF versus standard care over a median 33-m

Section: CardiologyNov 21, 2025

Mobile Integrated Health vs Transitions of Care in Heart Failure: Insights from the Mighty-Heart Trial

Mobile Integrated Health vs Transitions of Care in Heart Failure: Insights from the Mighty-Heart Trial

A large clinical trial compared Mobile Integrated Health with standard care coordination for heart failure patients after hospital discharge, finding no significant overall benefits but highlighting potential age-related effects.

Section: CardiologyNov 18, 2025

Cardiotropic AAV Gene Therapy (AB-1002) Shows Early Safety and Signals of Efficacy in Phase 1 Heart Failure Trial

Cardiotropic AAV Gene Therapy (AB-1002) Shows Early Safety and Signals of Efficacy in Phase 1 Heart Failure Trial

Phase 1 study of AB-1002 (cardiotropic AAV delivering I-1c) in 11 patients with nonischemic HFrEF showed feasibility, no treatment-attributed SAEs, transient LFT elevations at higher dose, and preliminary signals of improved LVEF and NYHA c

Section: CardiologyNov 13, 2025

Warm and Cold Risks: How Temperature Variations Impact Mortality in Swedish Heart Failure Patients

Warm and Cold Risks: How Temperature Variations Impact Mortality in Swedish Heart Failure Patients

This study reveals that both low and high ambient temperatures significantly increase mortality risk among Swedish heart failure patients, highlighting the need for climate adaptation strategies in high-latitude regions.

Section: CardiologyOct 25, 2025

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.

Section: CardiologyOct 24, 2025

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials

Pooled data from VICTORIA and VICTOR trials demonstrate that vericiguat significantly reduces cardiovascular death and heart failure hospitalization in a wide spectrum of patients with heart failure and reduced ejection fraction, including

Section: CardiologyOct 11, 2025

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with accept

Section: CardiologyOct 11, 2025

Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications

Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Patients with Heart Failure: Prevalence, Genetics, and Clinical Implications

A prospective study reveals transthyretin cardiac amyloidosis (ATTR-CA) affects a significant proportion of older Black patients with heart failure, especially men over 75, with nearly half linked to the V142I genetic variant. Hispanic prev

Section: CardiologyOct 9, 2025

Comparing Cardiac MRI and Coronary Angiography for Diagnosing Ischemic Cardiomyopathy in New-Onset Heart Failure

Comparing Cardiac MRI and Coronary Angiography for Diagnosing Ischemic Cardiomyopathy in New-Onset Heart Failure

A multicenter trial shows cardiac MRI offers comparable sensitivity to invasive coronary angiography for diagnosing ischemic cardiomyopathy, reducing invasive procedures in newly diagnosed heart failure patients.

Section: CardiologyOct 9, 2025

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential fo

Section: CardiologyOct 9, 2025

Nutritional Intervention in Chronic Heart Failure: Enhancing Functional Capacity and Nutritional Status without Major Clinical Outcome Impact

Nutritional Intervention in Chronic Heart Failure: Enhancing Functional Capacity and Nutritional Status without Major Clinical Outcome Impact

A prespecified subanalysis of the PACMAN-HF trial demonstrates that individualized nutritional interventions in chronic heart failure patients at risk of malnutrition improve nutritional status and functional capacity but do not significant

Section: Diabetes & EndocrinologyOct 8, 2025

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFp

Section: CardiologyOct 8, 2025

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.

Section: CardiologyOct 7, 2025

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF i

Section: CardiologyOct 7, 2025

Prev 1 3 4 5 6 7 Next